Despite the currently available drug treatment alternatives, a substantial group of patients with ulcerative colitis suffer from difficult symptoms such as pain and frequent, bloody diarrhea.
InDex Pharmaceuticals lead drug candidate is cobitolimod – a new type of drug that can help patients back to a normal life. InDex has also developed a platform of patent protected substances, so called DNA based ImmunoModulatory Sequences (DIMS), with the potential to be used in treatment of various immunological diseases.
The company is based at the Karolinska Institutet Science Park in Stockholm. Among the main shareholders are Linc AB, HBM Healthcare Investments, 4th AP Fund and Handelbanken Läkemedelsfond.
InDex Pharmaceuticals Holding AB (publ) is the parent company of the Group, which also includes InDex Pharmaceuticals AB and InDex Pharmaceuticals AB’s wholly owned subsidiary InDex Diagnostics AB.